A PHASE III, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, 48 WEEK STUDY WITH AN INITIAL 12 WEEK PLACEBO-CONTROLLED PERIOD TO EVALUATE THE SAFETY AND EFFICACY OF OSILODROSTAT IN PATIENTS WITH CUSHING¿S DISEASE

Registry ID

CLCI699C2302

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2019-01-28

Completion date

2020-12-31

Last update

2017-05-02

Conditions

• CUSHING'S DISEASE

View on source registry